Mimedx (MDXG) Current Deferred Revenue (2011 - 2012)

Mimedx (MDXG) reported Current Deferred Revenue of $6620.0 for Q1 2012, little changed sequentially from $6620.0 in Q4 2011.

Mimedx (MDXG) Current Deferred Revenue (2011 - 2012) Analysis & Trends

Mimedx (MDXG) has 2 years of Current Deferred Revenue data on file, last reported at $6620.0 in Q1 2012.

For the quarter ending Q1 2012, Current Deferred Revenue changed N/A year-over-year to $6620.0; the trailing twelve-month figure through Mar 2012 stood at $6620.0 (changed N/A YoY), and the FY2011 full-year result was $6620.0, changed N/A from the prior year.
Current Deferred Revenue was little changed at $6620.0 in Q1 2012, from $6620.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $6620.0 in Q2 2011 to a low of $6620.0 in Q2 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Mimedx	615.09 Mn	455.31 Mn	41.62 Mn

Download Data